We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Determining Fibrosis Stage in Non-Alcoholic Fatty Liver Disease

By LabMedica International staff writers
Posted on 24 Sep 2018
Print article
Image: A micrograph of non-alcoholic fatty liver disease, demonstrating marked steatosis (fatty liver appears white) (Photo courtesy of Wikimedia Commons).
Image: A micrograph of non-alcoholic fatty liver disease, demonstrating marked steatosis (fatty liver appears white) (Photo courtesy of Wikimedia Commons).
Measurement of a specific biomarker identifies advanced fibrosis in patients with non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver, which occurs when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Given the high global prevalence of NAFLD, the need for relevant non‐invasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need. Identifying those with advanced fibrosis is the most crucial, as these individuals have the greatest risk of adverse, long‐term, liver‐related outcomes.

In an effort to establish a diagnostic test, investigators at Westmead Institute for Medical Research (Australia) evaluated the role of PRO‐C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD.

The investigators measured PRO‐C3 by enzyme‐linked immunosorbent assay (ELISA) in two large independent cohorts with extensive clinical phenotyping and liver biopsy; 150 in the derivation and 281 in the validation cohort. A PRO‐C3 based fibrosis algorithm (ADAPT) was developed that included age, presence of diabetes, PRO‐C3, and platelet count.

Results revealed that PRO‐C3 increased with fibrosis stage and was independently associated with advanced fibrosis. Findings, as interpreted by the ADAPT algorithm, accurately identified 92% of patients with advanced fibrosis and were superior to the existing fibrosis scores, aspartate aminotransferase (AST) to platelet ratio index (APRI), FIB‐4 and NAFLD fibrosis score (NFS).

"Given the high global prevalence of non-alcoholic fatty liver disease, we need a non-invasive clinical tool to accurately measure fibrosis," said senior author Dr. Jacob George, professor of gastroenterology at Westmead Institute for Medical Research. The tool would help to identify patients at greatest risk poor long-term health outcomes."

The study was published in the July 16, 2018, online edition of the journal Hepatology.

Related Links:
Westmead Institute for Medical Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more